Relay Therapeutics, Inc. (RLAY) recently announced that it had achieved positive interim data from its ongoing phase 1 ReDiscover study, using its drug RLY-2608 + fulvestrant for the treatment of ...
In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback